Related Experiment Video
Updated: Jun 27, 2026
07:59
A High Throughput MHC II Binding Assay for Quantitative Analysis of Peptide Epitopes
Published on: March 25, 2014
15.1K
High-throughput epigenetic profiling immunoassays for accelerated disease research and clinical development
Priscilla Van den Ackerveken1, Clotilde Hannart1, Dorian Pamart1
1Belgian Volition SRL, Parc Scientifique Crealys, Isnes, Belgium.
The Journal of Biological Chemistry
|June 9, 2025
Summary
New immunoassays accurately detect histone post-translational modifications (PTMs) in various samples, offering a scalable tool for epigenetic profiling and biomarker discovery in diseases like cancer.
Area of Science:
- Epigenetics and molecular biology
- Biomarker discovery and diagnostics
Background:
- Epigenetics regulates gene expression without altering DNA sequence.
- Histone post-translational modifications (PTMs) are key epigenetic regulators.
- Aberrant histone PTMs are linked to diseases, including cancer, necessitating robust detection methods.
Purpose of the Study:
- To develop and validate novel immunoassays for detecting histone PTMs.
- To assess the utility of these assays across diverse biological sample types.
- To provide a scalable and sensitive method for epigenetic profiling.
Main Methods:
- Development and validation of 13 Nu.Q immunoassays.
- Testing assays on K2EDTA plasma, tissue chromatin extracts, cell lines, and white blood cells.
- Comparative analysis with mass spectrometry and Western blotting.
Main Results:
- Nu.Q assays demonstrated high specificity, sensitivity, precision, and linearity.
- Consistent histone PTM signatures were observed across different detection methods.
- Successful application of assays in human tissues and specific white blood cell subtypes.
Conclusions:
- Nu.Q immunoassays are effective tools for epigenetic profiling.
- The assays are versatile and applicable to various biological samples.
- This technology holds promise for biomarker discovery and understanding disease mechanisms.
